Heparin-binding epidermal growth factor-like growth factor inhibits cytokine-induced NF-κB activation and nitric oxide production via activation of the phosphatidylinositol 3-kinase pathway

Journal of Immunology

Volumn 175, Issue 3, 2005, Pages 1911-1918

  Mehta, Veela B ^a   Besner, Gail E ^a,b,c  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 8; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 22544485647     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.3.1911     Document Type: Article

References (41)

1. Grisham, M. B., K. P. Pavlick, F. S. Laroux, J. Hoffman, S. Bharwani, and R. E. Wolf: 2002. Nitric oxide and chronic gut inflammation: controversies in inflammatory bowel disease. J. Investig. Med. 50: 272-283.
2. Barrachina, M. D., J. Panes, and J. V. Esplugues. 2001. Role of nitric oxide in gastrointestinal inflammatory and ulcerative diseases: perspective for drugs development. Curr. Pharm. Des. 7: 31-48.
3. Caplan, M. S., and W. MacKendrick. 1994. Inflammatory mediators and intestinal injury. Clin. Perinatol. 21: 235-246.
4. Bonni, A., A. Brunet, A. E. West, S. R. Datta, M. A. Takasu, and M. E. Greenberg. 1999. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286: 1358-1362.
5. Erhardt, P., E. J. Schremser, and G. M. Cooper. 1999. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol. Cell Biol. 19: 5308-5315.
6. Merlot, S., and R. A. Firtel. 2003. Leading the way: Directional sensing through phosphatidylinositol 3-kinase and other signaling pathways. J. Cell Sci. 116: 3471-3478.
7. Wymann, M. P., M. Zvelebil, and M. Laffargue. 2003. Phosphoinositide 3-kinase signalling: which way to target? Trends Pharmacol. Sci. 24: 366-376.
8. Pyo, H., M. S. Yang, I. Jou, and E. H. Joe. 2003. Wortmannin enhances lipopolysaccharide-induced inducible nitric oxide synthase expression in microglia in the presence of astrocytes in rats. Neurosci. Lett. 346: 141-144.
9. Pahan, K., J. R. Raymond, and I. Singh. 1999. Inhibition of phosphatidylinositol 3-kinase induces nitric-oxide synthase in lipopolysaccharide- or cytokine-stimulated C6 glial cells. J. Biol. Chem. 274: 7528-7536.
10. Diaz-Guerra, M. J., A. Castrillo, P. Martin-Sanz, and L. Bosca. 1999. Negative regulation by phosphatidylinositol 3-kinase of inducible nitric oxide synthase expression in macrophages. J. Immunol. 162: 6184-6180.
11. Mehta, V. B., and G. E. Besner. 2003. Inhibition of NF-κB activation and its target genes by heparin-binding epidermal growth factor-like growth factor. J. Immunol. 171: 6014-6022.
12. Xie, Q. W., Y. Kashiwabara, and C. Nathan. 1994. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J. Biol. Chem. 269: 4705-4708.
13. Barnes, P. J., and M. Karin. 1997. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336: 1066-1071.
14. Schottelius, A. J., and A. S. Baldwin, Jr. 1999. A role for transcription factor NF-κB in intestinal inflammation. Int. J. Colorectal Dis. 14: 18-28.
15. Besner, G., S. Higashiyama, and M. Klagsbrun. 1990. Isolation and characterization of a macrophage-derived heparin-binding growth factor. Cell Regul 1: 811-819.
16. Naglich, J. G., J. E. Metherall, D. W. Russell, and L. Eidels. 1992. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 69: 1051-1061.
17. Davis-Fleischer, K. M., and G. E. Besner. 1998. Structure and function of heparin-binding EGF-like growth factor (HB-EGF). Front. Biosci. 3:d288-d299.
18. Biswas, D. K., A. P. Cruz, E. Gansberger, and A. B. Pardee. 2000. Epidermal growth factor-induced nuclear factor κB activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. USA 97: 8542-8547.
19. Chen, D., L. G. Xu, L. Chen, L. Li, Z. Zhai, and H. B. Shu. 2003. NIK is a component of the EGF/heregulin receptor signaling complexes. Oncogene 22: 4348-4355.
20. Iwamoto, R., and E. MEKada. 2000. Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev. 11: 335-342.
21. Vaughan, T. J., J. C. Pascall, and K. D. Brown. 1992. Tissue distribution of mRNA for heparin-binding epidermal growth factor. Biochem. J. 287(Pt 3): 681-684.
22. Pillai, S. B., C. E. Hinman, M. H. Luquette, P. T. Nowicki, and G. E. Besner. 1999. Heparin-binding epidermal growth factor-like growth factor protects rat intestine from ischemia/reperfusion injury. J. Surg. Res. 87: 225-231.
23. Farakas, L. M., and K. K. 2002. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) regulates survival of midbrain dopaminergic neurons. J. Neural Transm. 109: 267-277.
24. Takemura, T., S. Kondo, T. Homma, M. Sakai, and R. C. Harris. 1997. The membrane-bound form of heparin-binding epidermal growth factor-like growth factor promotes survival of cultured renal epithelial cells. J. Biol. Chem. 272: 31036-31042.
25. Miyoshi, E., S. Higashiyama, T. Nakagawa, N. Hayashi, and N. Taniguchi. 1997. Membrane-anchored heparin-binding epidermal growth factor-like growth factor acts as a tumor survival factor in a hepatoma cell line. J. Biol. Chem. 272: 14349-14355.
26. Michalsky, M. P., A. Kuhn, V. Mehta, and G. E. Besner. 2001. Heparin-binding EGF-like growth factor decreases apoptosis in intestinal epithelial cells in vitro. J. Pediatr. Surg. 36: 1130-1135.
27. Lara-Marquez, M. L., V. Mehta, M. P. Michalsky, J. B. Fleming, and G. E. Besner. 2002. Heparin-binding EGF-like growth factor down regulates proinflammatory cytokine-induced nitric oxide and inducible nitric oxide synthase production in intestinal epithelial cells. Nitric Oxide 6: 142-152.
28. Davis, K. M., D. R. Brigstock, P. R. Johnson, M. A. Crissman-Combs, D. W. McCarthy, M. T. Downing, and G. E. Besner. 1996. Production of glycosylated heparin-binding EGF-like growth factor in HeLa cells using vaccinia virus. Protein Expr. Purif. 8: 57-67.
29. Brunet, A., A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. Blenis, and M. E. Greenberg. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
30. Mansour, S. J., W. T. Matten, A. S. Hermann, J. M. Candia, S. Rong, K. Fukasawa, G. F. Vande Woude, and N. G. Ahn. 1994. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970.
31. Irani, K., Y. Xia, J. L. Zweier, S. J. Sollot, C. J. Der, E. R. Fearon, M. Sundaresan, T. Finkel, and P. J. Goldschmidt-Clermont. 1997. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275: 1649-1652.
32. Dignam, J. D., R. M. Lebovitz, and R. G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11: 1475-1489.
33. Spink, J., J. Cohen, and T. J. Evans. 1995. The cytokine responsive vascular smooth muscle cell enhancer of inducible nitric oxide synthase. Activation by nuclear factor-κB. J. Biol. Chem. 270: 29541-29547.
34. Flodstrom, M., N. Welsh, and D. L. Eizirik. 1996. Cytokines activate the nuclear factor κB (NF-κB) and induce nitric oxide production in human pancreatic islets. FEBS Lett. 385: 4-6.
35. Chen, Y. Q., J. H. Fisher, and M. H. Wang. 1998. Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression. J. Immunol. 161: 4950-4959.
36. Pahan, K., F. G. Sheikh, A. M. Namboodiri, and I. Singh. 1997. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100: 2671-2679.
37. Ayasolla, K., M. Khan, A. K. Singh, and I. Singh. 2004. Inflammatory mediator and β-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radic. Biol. Med. 37: 325-338.
38. Arber, N., and R. N. DuBois. 1999. Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr. Gastroenterol Rep. 1: 441-449.
39. Potoka, D. A., E. P. Nadler, J. S. Upperman, and H. R. Ford. 2002. Role of nitric oxide and peroxynitrite in gut barrier failure. World J. Surg. 26: 806-811.
40. Merial-Kieny, C., M. Lonchampt, F. Coge, P. Verwaerde, J. P. Galizzi, J. A. Boutin, M. Lafontan, N. Levens, J. Galitzky, and M. Feletou. 2003. Endothelin-1 inhibits TNF α-induced iNOS expression in 3T3-F442A adipocytes. Br. J. Pharmacol. 139: 935-944.
41. Kitagawa, K., Y. Hamada, Y. Kato, K. Nakai, M. Nishizawa, S. Ito, and T. Okumura. 2004. Epidermal growth factor and interleukin-1β synergistically stimulate the production of nitric oxide in rat intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G1188-G1193.